Kanamycin

• Description :

  Kanamycin (Kanamycin A) is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia[1][2][3][4].

• CAS Number :

  [59-01-8]

• Product Name Alternative :

  Kanamycin A

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Antibiotic; Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/kanamycin.html

• Purity :

  99.97

• Solubility :

  H2O : 70 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O[C@H]1[C@](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)([H])O[C@H](CN)[C@@H](O)[C@@H]1O

• Molecular Formula :

  C18H36N4O11

• Molecular Weight :

  484.50

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]YANAGISAWA K, et al. Studies on kanamycin, a new antibiotic against tubercle bacilli. I. Effect on virulent tubercle bacilli in vitro and in mice. J Antibiot (Tokyo) . 1957 Nov;10 (6) :233-5. |[2]Nishi T, et al. Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: chemotherapy with kanamycin. Antimicrob Agents Chemother. 1980 Mar;17 (3) :494-505.|[3]Misumi M, et al. Interaction of kanamycin and related antibiotics with the large subunit of ribosomes and the inhibition of translocation. Biochem Biophys Res Commun. 1978 Sep 29;84 (2) :358-65. |[4]Misumi M, et al. Mechanism of inhibition of translocation by kanamycin and viomycin: a comparative study with fusidic acid. Biochem Biophys Res Commun. 1980 Jan 29;92 (2) :647-54.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  Aminoglycoside

• Citation 01 :

  ACS Infect Dis. 2025 Apr 11;11 (4) :929-939.|Adv Sci (Weinh) . 2024 Aug;11 (31) :e2308307.|AMB Express. 2024 Dec 24;14 (1) :141.|Aquat Toxicol. 2025 Feb 9:280:107284.|bioRxiv. 2025 January 19.|bioRxiv. 2025 May 29.|BMC Microbiol. 2025 Apr 29;25 (1) :257.|Commun Biol. 2025 Oct 6;8 (1) :1425.|Food Chem. 2023 Mar 1:403:134399.|Int Immunopharmacol. 2025 May 21:159:114888.|Int J Med Microbiol. 2023 Mar 28;313 (2) :151578.|iScience. 2025 Nov 12;28 (12) :114030.|J Periodontol. 2024 Sep;95 (9) :867-879.|Microbiol Spectr. 2025 Aug 29:e0059025.|Microbiol Spectr. 2025 Oct 16:e0160325.|mLife. 2025 Apr 15;4 (2) :155-168.|Nat Microbiol. 2025 Nov;10 (11) :2949-2965.|Vet Res Commun. 2024 Dec;48 (6) :3859-3872.|ACS Chem Biol. 2022 Jan 21;17 (1) :39-53.|ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|Cell Death Dis. 2021 May 18;12 (6) :509.|Chin Med. 2025 Oct 3;20 (1) :155.|Int J Hydrogen Energy. 2018, 43 (30), 13821-13828.|Microb Biotechnol. 2021 Nov;14 (6) :2538-2551.|Nucleic Acids Res. 2022 Dec 9;50 (22) :12951-12968.|Sci Adv. 2023 Feb 17;9 (7) :eade4770.